Shin Kong Life Insurance appeared to be the Corporate Investor, which was created in 1963.
Among the most popular fund investment industries, there are Pharmaceutical, Health Care. Among the various public portfolio startups of the fund, we may underline TaiGen Biotechnology Besides, a startup needs to be aged 2-3 years to get the investment from the fund.
The fund is generally included in less than 2 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2004.
The typical case for the fund is to invest in rounds with 7 participants. The meaningful sponsors for the fund in investment in the same round are YFY Inc., Major Series A, MPM Capital. In the next rounds fund is usually obtained by YFY Inc., YFY Biotech Management Company, Taiwan Sugar Corporation.
Related Funds
| Fund Name | Location |
| Anduin Capital | California, Mountain View, United States |
| DPS | China, Guangdong, Shenzhen |
| Enova International | Chicago, Illinois, United States |
| Enzo Ventures | - |
| G-Bar Ventures | - |
| G7 Renewable Energies | Gauteng, NA - South Africa, South Africa |
| Hongdao Dianying Jinrong | China, Hangzhou, Zhejiang |
| HSBC Venture Capital Coverage Group | California, San Francisco, United States |
| IMG Investment Partners | - |
| Madera Technology Partners | New York, New York, United States |
| Mofet Technology Fund | Herzliya, Israel, Tel Aviv |
| Nanjing Guanghe Hudong Touzi | China, Jiangsu, Nanjing |
| Naturals | Chennai, India, Tamil Nadu |
| SBI Japan-Israel Innovation Fund | Israel, Tel Aviv, Tel Aviv District |
| Shiga Bank | Japan, Otsu, Shiga Prefecture |
| Still Venture Capital | - |
| Tackle Capital | - |
| Vision Capital | Geneva, Geneve, Switzerland |
| XL Ventures | New York, New York, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
TaiGen Biotechnology | $38M | 16 Mar 2004 | New Taipei, Taiwan |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
TaiGen Biotechnology | $38M | 16 Mar 2004 | New Taipei, Taiwan |
